Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03950414 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03950414 is a Phase 1 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 2 participants.
The verdict
NCT03950414, a Phase 1 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study measures the tolerability of viral-specific T cells against Cytomegalovirus (CMV) in adult solid organ transplant (SOT) recipients. Participants are expected to be on study for 52 +/- 3 weeks.
Interventions
- BIOLOGICAL CMV specific T-cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-09-27 |
| Est. Completion | 2022-07-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03950414
The ClinicalTrials.gov registry entry for NCT03950414 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CMV specific T-cells is the first listed.
NCT03950414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03950414 about?
NCT03950414 is a clinical study titled "A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients". This study measures the tolerability of viral-specific T cells against Cytomegalovirus (CMV) in adult solid organ transplant (SOT) recipients. Participants are expected to be on study for 52 +/- 3 weeks.
What is the current status of trial NCT03950414?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-09-27. Estimated completion is 2022-07-11.
What interventions are being tested in trial NCT03950414?
The interventions under investigation include: CMV specific T-cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03950414?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.